Lescol
Product Images NDC 54868-3329

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Lescol (NDC 54868-3329). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Physicians Total Care, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image Of 20 mg Package Label (3329)

Label for LESCOL 20 MG capsules distributed by Physicians Total Care, Inc. The label includes the NDC 54868-3329-0 and indicates a package of 30 capsules. It also shows a lot number and an expiration date listed as 01/60, with manufacturing by Novartis Pharmaceuticals C, Suffern, NY.*

FDA Label Image

Image Of 40 mg Package Label (4224)

Label for LESCOL 40MG capsules, containing 30 capsules, distributed by Physicians Total Care, Inc. The label includes the NDC number 54868-4224-0, lot number 0000, and an expiration date of 01/60. It also notes the medication is manufactured by Novartis Pharmaceuticals in Suffern, NY. A barcode is present at the bottom of the label.*

FDA Label Image

Image Of Chemcial Structure (Lescol 02)

Chemical structure of the active ingredient in LESCOL, displaying atoms including fluorine (F), sodium (Na), and molecular formula C24H25FNO4 · Na with a molecular weight of 433.46.*

FDA Label Image

Image Of Figure 1 Graph (Lescol 03)

A Kaplan-Meier survival curve graph comparing the percentage of patients without events over time in years since randomization between Fluvastatin 80 mg and placebo groups. The graph displays survival rates on the vertical axis and years since randomization on the horizontal axis, including statistical data such as Cox and Log-Rank P values and hazard ratio with confidence intervals.*

FDA Label Image

Image Of Figure 2 Chart (Lescol 04)

A forest plot chart illustrating the incidence of various cardiac events comparing Lescol and placebo groups. The chart displays percentage values for Lescol and placebo groups, risk reduction percentages, and Cox risk ratios with 95% confidence intervals. The events include primary endpoint recurrent cardiac events and several secondary endpoints such as cardiac death, nonfatal myocardial infarction, and revascularization.*

FDA Label Image

Image Of Figure 3 Chart (Lescol 05)

A bar chart titled 'Change in Minimum Lumen Diameter (mm)' comparing different patient groups—Monotherapy, All Patients, and All Patients + Calcium Channel Therapy. It shows negative changes in minimum lumen diameter for LESCOL and Placebo within each group, indicating measurements related to vascular changes.*

FDA Label Image

Image Of Figure 4 Chart (Lescol 06)

A bar chart titled 'Change in % Diameter Stenosis' comparing LESCOL and placebo groups across three categories: Miscellaneous, All Patients, and LESCOL with placebo (ARP-Calcium channel blocker). The chart shows percentage changes with vertical bars and indicates statistical significance with p-values between groups.*

FDA Label Image

Image Of Symbol (Lescol 07)

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.